Similar articles

• The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients.

  Ghods AJ, Milanian I, Arghani H, Ghadiri G. Ghods AJ, et al. Transplant Proc. 1995 Oct;27(5):2579-80. Transplant Proc. 1995. PMID: 7482835 No abstract available.
• Impact of fluvastatin on hyperlipidemia after renal transplantation.

  Tokumoto T, Tanabe K, Ishida H, Shimmura H, Ishikawa N, Goya N, Akiba T, Toma H. Tokumoto T, et al. Transplant Proc. 2004 Sep;36(7):2141-4. doi: 10.1016/j.transproceed.2004.06.027. Transplant Proc. 2004. PMID: 15518777 Clinical Trial.
• Efficacy and safety of treatment with low-dose fluvastatin in hypercholesterolemic renal transplant recipients.

  Akiyama T, Ishii T, Imanishi M, Nishioka T, Matsuura T, Kurita T. Akiyama T, et al. Transplant Proc. 2001 May;33(3):2115-8. doi: 10.1016/s0041-1345(01)01966-2. Transplant Proc. 2001. PMID: 11377469 Clinical Trial. No abstract available.
• [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].

  Carmena R. Carmena R. Rev Esp Cardiol. 1995 Jan;48(1):59-65. Rev Esp Cardiol. 1995. PMID: 7878284 Review. Spanish. No abstract available.
• The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.

  Holdaas H, Wanner C, Abletshauser C, Gimpelewicz C, Isaacsohn J. Holdaas H, et al. Int J Cardiol. 2007 Apr 12;117(1):64-74. doi: 10.1016/j.ijcard.2006.06.003. Epub 2006 Aug 4. Int J Cardiol. 2007. PMID: 16889855 Review.